What is the recommended management of sleep disturbance in an older adult, including non‑pharmacologic measures and safe pharmacologic options?

Management of Sleep Disturbances in Older Adults

Cognitive behavioral therapy for insomnia (CBT-I) must be initiated as first-line treatment before any pharmacologic agent in elderly patients with sleep disturbances, and if medication becomes necessary after CBT-I failure, use ramelteon 8 mg for sleep-onset problems or low-dose doxepin 3–6 mg for sleep-maintenance insomnia—never benzodiazepines. 1, 2

Initial Assessment: Identify Reversible Contributors

Before implementing any treatment, systematically evaluate four critical domains that commonly disrupt sleep in older adults:

Medication Review

• Screen for sleep-disrupting medications: β-blockers (propranolol, metoprolol, atenolol), diuretics taken in the evening, bronchodilators, systemic corticosteroids, decongestants, and SSRIs/SNRIs all frequently cause or worsen insomnia in elderly patients. 1
• Consider switching β-blockers to alternative antihypertensives (thiazide diuretics, calcium-channel blockers, ACE inhibitors, or ARBs) when insomnia is present. 1
• Time diuretics appropriately: Evening administration produces nocturia that fragments sleep; shift to morning dosing. 1

Screen for Primary Sleep Disorders

• Obstructive sleep apnea affects 24% of elderly patients and will undermine insomnia treatment if unrecognized. 2
• Restless legs syndrome occurs in 12% and periodic limb movements in 45% of older adults; both require specific therapy before addressing insomnia. 2
• Untreated comorbid sleep disorders diminish treatment efficacy for insomnia. 1

Evaluate Sleep-Impairing Behaviors

• Excessive time in bed during the day, prolonged daytime napping, insufficient physical activity, evening alcohol consumption, and late heavy meals all disrupt nocturnal sleep consolidation. 1

Medical Comorbidities

• Pain, paresthesias, nighttime cough, dyspnea, gastroesophageal reflux, and nocturia commonly interfere with sleep in nursing home and community-dwelling elderly. 3
• Neurodegenerative disorders (dementia, Parkinson's disease) are strongly associated with sleep disturbance and require tailored approaches. 3

---

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I provides superior long-term outcomes compared to medications, with sustained effects for up to 2 years and no polypharmacy risks, falls, cognitive impairment, or fracture risk. 1, 2

The American College of Physicians states that CBT-I offers greater overall value than pharmacologic therapy because it is non-invasive and carries fewer serious harms, including dementia, serious injury, and fractures. 1

Core CBT-I Components to Implement

Sleep Restriction/Compression Therapy

• Have the patient keep a 1–2 week sleep log to calculate mean total sleep time (TST). 1
• Prescribe time-in-bed (TIB) to match calculated TST while maintaining sleep efficiency ≥85%; never set TIB below 5 hours. 1
• Adjust TIB weekly: increase by 15–20 minutes if sleep efficiency >85–90%; decrease by 15–20 minutes if <80%. 1
• Sleep compression (gradual reduction) is better tolerated by elderly patients than immediate restriction. 1

Stimulus Control

• Use the bedroom only for sleep and sex—no television, reading, or worrying in bed. 1, 2
• Leave the bedroom if unable to fall asleep within 15–20 minutes; return only when sleepy. 1, 2
• Maintain consistent sleep and wake times every day, including weekends. 1
• Avoid daytime napping or strictly limit to <30 minutes before 3 PM. 1

Sleep Hygiene Modifications

• Environmental: Keep bedroom cool, dark, and quiet; use blackout curtains and white noise if needed. 1
• Dietary: Avoid caffeine, nicotine, and alcohol in the evening; avoid heavy meals within 2 hours of bedtime. 1
• Activity: Avoid vigorous exercise within 2 hours of bedtime; limit fluids before sleep to reduce nocturia. 1
• Critical caveat: Sleep hygiene education alone is insufficient for chronic insomnia and must be combined with other CBT-I modalities. 1, 2

Relaxation Techniques

• Progressive muscle relaxation, guided imagery, or diaphragmatic breathing help achieve a calm state conducive to sleep onset. 1

CBT-I Delivery and Accessibility

• CBT-I can be delivered within primary-care settings, making it readily accessible for routine practice in older adults. 1
• Effects are sustained for up to 2 years without medication-related risks such as falls, cognitive impairment, fractures, and dementia. 1

---

Second-Line Treatment: Pharmacotherapy (Only After CBT-I Failure)

Pharmacotherapy should only be initiated after CBT-I has been attempted, using shared decision-making that discusses benefits, harms, and costs of short-term medication use. 1, 2

Medication Selection Based on Symptom Pattern

For Sleep-Onset Insomnia

• Ramelteon 8 mg at bedtime is the first-choice agent—a melatonin-receptor agonist that does not require DEA licensure and aids circadian-rhythm regulation. 1, 2
• Short-acting Z-drugs (zolpidem 5 mg immediate-release) are an alternative for sleep-onset insomnia in elderly patients. 1

For Sleep-Maintenance Insomnia

• Low-dose doxepin 3–6 mg is the most appropriate medication, with demonstrated improvement in total sleep time, wake after sleep onset, and sleep quality. 1, 2
• Suvorexant (orexin receptor antagonist) is an alternative for sleep-maintenance problems. 1

For Combined Sleep-Onset and Maintenance Insomnia

• Eszopiclone 1–2 mg (start at 1 mg) is appropriate for combined symptoms in older adults, without a short-term usage restriction. 1
• Extended-release zolpidem 6.25 mg is another option for combined insomnia symptoms. 1

Dosing Principles in Elderly Patients

• Start at the lowest available dose due to reduced drug clearance and increased sensitivity to peak effects. 1, 2
• Follow patients every few weeks initially to assess effectiveness and side effects. 1, 2
• Employ the lowest effective maintenance dosage and taper when conditions allow. 1

Duration of Pharmacotherapy

• FDA-approved hypnotics are indicated for short-term use (typically 4–5 weeks); prolonged continuous use is discouraged. 1
• For patients requiring chronic hypnotic medication due to severe or refractory insomnia, administration may be nightly, intermittent (three nights per week), or as needed, with consistent follow-up and ongoing assessment. 1, 2
• Patients should receive an adequate trial of CBT-I during long-term pharmacotherapy whenever possible. 1, 2
• Medication tapering and discontinuation are facilitated by CBT-I. 1

Combination Therapy

• Combining CBT-I with pharmacotherapy may provide better short-term outcomes than either modality alone, with medications providing rapid onset relief and behavioral therapy providing longer-term sustained benefit. 1, 2

---

Medications to Strictly Avoid in Older Adults

Benzodiazepines (Contraindicated as First-Line)

• Benzodiazepines (temazepam, lorazepam, clonazepam, triazolam, flurazepam, quazepam) are contraindicated as first-line agents in older adults because they raise the risk of falls, cognitive impairment, dependence, and dementia. 1, 2
• Long-term use of benzodiazepines, even at low intermittent doses, is associated with an increased risk of dementia, particularly with higher doses and longer half-lives. 1
• A randomized trial showed temazepam caused poorer neurologic function and more daytime hypersomnolence in nursing home residents. 1

Over-the-Counter Antihistamines

• Diphenhydramine and hydroxyzine should be avoided in elderly patients due to anticholinergic effects that can accelerate cognitive decline and cause daytime hypersomnolence. 1, 2
• Hydroxyzine in patients with potential cognitive decline can accelerate dementia progression. 1

Sedating Antidepressants

• Trazodone, amitriptyline, doxepin (at higher doses), and mirtazapine should only be used when comorbid depression or anxiety exists, as there is no systematic evidence for effectiveness in primary insomnia and risks outweigh benefits. 1, 2
• Tricyclic antidepressants have anticholinergic burden that is particularly hazardous in older adults with frailty and potential cognitive decline. 1

Other Agents to Avoid

• Barbiturates, chloral hydrate, and herbal supplements (valerian, melatonin) are not recommended due to lack of efficacy and safety data. 1, 2
• Bronchodilators, corticosteroids, and decongestants may impair sleep when used for comorbid conditions and should be reviewed during insomnia assessment. 1

---

Special Population: Nursing Home Residents

Implement a multicomponent approach combining increased daytime physical activity and sunlight exposure, decreased time in bed during the day, structured bedtime routines, and minimized nighttime noise and light interruptions. 2

Environmental Modifications

• Decrease nighttime noise and light disruption to reduce nighttime arousals. 1
• Improve incontinence care to minimize nighttime awakenings. 1

Activity and Light Exposure

• Increase daytime physical activity and ensure at least 30 minutes of sunlight exposure daily. 1
• Reduce time spent in bed during the day to consolidate nighttime sleep. 1

Structured Routines

• Establish a structured bedtime routine to provide temporal cues. 1

---

Special Population: Patients with Dementia or Alzheimer's Disease

Prioritize non-pharmacological interventions such as bright light therapy, physical activity, and structured routines; the American Academy of Sleep Medicine issues a STRONG AGAINST recommendation for any sleep-promoting medications in elderly dementia patients due to increased risks of falls, cognitive decline, confusion, and other serious adverse outcomes that outweigh any potential sleep benefit. 4, 2

Non-Pharmacological Interventions (First-Line)

Bright Light Therapy (Primary Intervention)

• Administer 2,500–5,000 lux for 1–2 hours daily between 09:00 and 11:00 AM, positioned approximately 1 meter from the patient. 4
• Use LED-based light boxes that emit narrow-band blue-to-green light at 460–490 nm (478 nm optimal). 4
• Expected clinical improvement in sleep consolidation and behavior appears after 4–10 weeks of daily therapy. 4
• Bright light therapy decreases daytime napping, increases nighttime sleep, consolidates nighttime sleep, and reduces agitated behavior in patients with dementia. 4

Environmental Modifications

• Completely reduce exposure to bright light during nighttime hours and minimize noise during sleep hours. 4
• Improve incontinence care to reduce nighttime awakenings. 4
• Remove potentially dangerous objects from the bedroom for safety. 4

Activity and Routine

• Increase physical and social activities during daytime hours—stationary bicycle use, Tai Chi, and daily exercise programs have shown positive sleep effects. 4
• Ensure at least 30 minutes of daily sunlight exposure while reducing nighttime light exposure. 4
• Establish a structured bedtime routine to provide temporal cues. 4
• Strictly reduce time in bed during the day and discourage daytime napping. 4

Pharmacological Interventions (Strongly Discouraged)

• The American Academy of Sleep Medicine strongly recommends against using sleep-promoting medications (including melatonin, benzodiazepines, Z-drugs, antihistamines, suvorexant) in elderly patients with dementia and irregular sleep-wake rhythm disorder. 4
• Hypnotics increase risks of falls, cognitive decline, confusion, worsening cognitive impairment, anterograde amnesia, daytime sleepiness, and physical dependence. 4
• Melatonin has a WEAK AGAINST recommendation in elderly dementia patients due to lack of improvement in total sleep time and potential harm, including detrimental effects on mood and daytime functioning. 4
• High-quality randomized controlled trials show no benefit of melatonin in improving total sleep time in dementia patients. 4
• Altered pharmacokinetics in aging, especially with dementia, further increases medication risks. 4

---

Critical Monitoring Parameters During Pharmacotherapy

When using any sleep medication in elderly patients, monitor for:

• Respiratory depression 2
• Confusion or delirium 2
• Falls and fractures 2
• Next-day cognitive impairment 2
• Worsening dementia symptoms 2

Regular reassessment is necessary to evaluate treatment effectiveness, monitor for adverse effects, and assess for new or worsening comorbid disorders. 1

---

Common Pitfalls and How to Avoid Them

• Do not prescribe hypnotic medication before attempting CBT-I, as behavioral interventions provide superior long-term outcomes and reduce polypharmacy risk. 1
• Do not assume sleep hygiene education alone will suffice; it must be combined with other CBT-I modalities for chronic insomnia. 1
• Do not overlook medication-induced insomnia; β-blockers, SSRIs, and diuretics are common culprits in elderly patients. 1
• Do not default to benzodiazepines due to their unfavorable risk-benefit profile in elderly patients. 1, 2
• Do not use over-the-counter antihistamines (diphenhydramine, hydroxyzine) in elderly patients due to anticholinergic effects. 1, 2
• Do not treat sleep disturbances in dementia patients with pharmacotherapy first; implement non-pharmacological interventions and avoid sleep-promoting medications. 4